{"id":"cddp-5-fu","safety":{"commonSideEffects":["Nausea and vomiting","Myelosuppression","Nephrotoxicity","Mucositis","Diarrhea","Peripheral neuropathy"],"contraindications":["Severe renal impairment","Severe bone marrow suppression","Hypersensitivity to platinum compounds or fluoropyrimidines"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"DNA synthesis and repair pathways","explanation":"Cisplatin forms platinum-DNA adducts that cause DNA crosslinks, triggering apoptosis. 5-Fluorouracil inhibits thymidylate synthase and incorporates into RNA/DNA, disrupting nucleotide synthesis. The combination provides synergistic cytotoxic effects through complementary mechanisms of DNA damage.","oneSentence":"Combines cisplatin's DNA crosslinking with 5-FU's inhibition of thymidylate synthase to disrupt DNA synthesis and repair in cancer cells."},"_scrapedAt":"2026-03-28T01:50:18.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122809,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"carboplatin and paclitaxel","brand":null,"company":null,"rationale":"Alternative platinum-taxane combination for solid tumors"},{"name":"FOLFOX","brand":null,"company":null,"rationale":"Oxaliplatin-based regimen for gastrointestinal cancers"},{"name":"pembrolizumab","brand":"Keytruda","company":"Merck","rationale":"Immunotherapy alternative for head and neck and gastric cancers"}],"description":"CDDP (cisplatin) and 5-FU (5-fluorouracil) is a combination chemotherapy regimen being investigated by Gustave Roussy Cancer Campus. This dual-agent approach combines a platinum-based compound with a fluoropyrimidine antimetabolite, commonly used in treating various solid tumors including head and neck, esophageal, and gastric cancers.","indications":{"approved":[{"status":"investigational","condition":"Head and neck cancer","patientPopulation":"Adult, various lines of therapy"},{"status":"investigational","condition":"Esophageal cancer","patientPopulation":"Adult, various lines of therapy"},{"status":"investigational","condition":"Gastric cancer","patientPopulation":"Adult, various lines of therapy"}]},"trialDetails":[{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT06535607","phase":"PHASE2","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-22","conditions":"Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","enrollment":257},{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT03715933","phase":"PHASE1","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2018-10-08","conditions":"Ewing Sarcoma","enrollment":321},{"nctId":"NCT02135042","phase":"PHASE2, PHASE3","title":"Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2014-04-21","conditions":"Epstein-Barr Virus Infection, Stage II Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma","enrollment":685},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT04083599","phase":"PHASE1, PHASE2","title":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2019-09-17","conditions":"Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":350},{"nctId":"NCT07276399","phase":"PHASE3","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":500},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06607185","phase":"PHASE1","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-21","conditions":"Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":750},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT05229497","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-05-04","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT06764875","phase":"PHASE3","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-01","conditions":"HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":840},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT05721755","phase":"PHASE3","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-06-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":290},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT06057038","phase":"PHASE1","title":"A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-11-24","conditions":"Malignant Solid Tumor","enrollment":42},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT06657144","phase":"PHASE1","title":"A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2025-04-01","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor","enrollment":154},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT05544136","phase":"PHASE2","title":"A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-12","conditions":"Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms","enrollment":12},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT07418866","phase":"PHASE2","title":"FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":70},{"nctId":"NCT06557889","phase":"PHASE2","title":"Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2024-10-21","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":86},{"nctId":"NCT06563479","phase":"PHASE3","title":"A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-08-19","conditions":"HPV-Related Squamous Cell Carcinoma","enrollment":291},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT06952621","phase":"PHASE3","title":"Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":390},{"nctId":"NCT03323463","phase":"PHASE2","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-10-16","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck","enrollment":316},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT07353177","phase":"","title":"Effects of HIPEC on Postoperative Bowel Motility and Complications","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-04-20","conditions":"HIPEC, Gastro Intestinal Cancer, Adhesion Prevention","enrollment":193},{"nctId":"NCT04229459","phase":"PHASE2","title":"Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baruch Brenner","startDate":"2020-02-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT06839378","phase":"NA","title":"Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei","status":"COMPLETED","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2025-02-17","conditions":"Pseudomyxoma Peritonei","enrollment":36},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT07043543","phase":"NA","title":"Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","status":"NOT_YET_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2026-01-15","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT03358472","phase":"PHASE3","title":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-12-01","conditions":"Head and Neck Cancer","enrollment":89},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT07256782","phase":"PHASE1, PHASE2","title":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-10-24","conditions":"Advanced Solid Tumor","enrollment":444},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT06632717","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT04854499","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":193},{"nctId":"NCT06010303","phase":"PHASE2","title":"A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-08","conditions":"Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage","enrollment":118},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT07076212","phase":"PHASE2","title":"Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-07","conditions":"Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":52},{"nctId":"NCT04926467","phase":"PHASE2","title":"Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2021-07-23","conditions":"Pancreatic Adenocarcinoma","enrollment":24},{"nctId":"NCT05307939","phase":"PHASE2","title":"A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-03-24","conditions":"HPV, Oropharynx Cancer, HPV-Related Carcinoma","enrollment":30},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT00082706","phase":"PHASE2","title":"Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-04-23","conditions":"Bladder Cancer, Urethral Cancer, Urachal Cancer","enrollment":46},{"nctId":"NCT05758389","phase":"PHASE2","title":"Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-04-01","conditions":"Head and Neck Tumors","enrollment":29},{"nctId":"NCT07156058","phase":"NA","title":"MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-01","conditions":"Biliary Tract Cancer","enrollment":204},{"nctId":"NCT03070366","phase":"PHASE2","title":"Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-09-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":78},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT04356170","phase":"PHASE2","title":"Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2021-02-04","conditions":"Cancer of Head and Neck","enrollment":105},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT05446467","phase":"PHASE2","title":"Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2022-09-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT02327078","phase":"PHASE1, PHASE2","title":"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2014-11-26","conditions":"B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer","enrollment":307},{"nctId":"NCT03314935","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-11-21","conditions":"Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer","enrollment":149},{"nctId":"NCT00716417","phase":"PHASE1","title":"Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07-01","conditions":"Neoplasms","enrollment":47},{"nctId":"NCT04675333","phase":"PHASE2","title":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ALX Oncology Inc.","startDate":"2021-05-10","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":172},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT03013218","phase":"PHASE1","title":"A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)","status":"COMPLETED","sponsor":"ALX Oncology Inc.","startDate":"2017-02-03","conditions":"Metastatic Cancer, Solid Tumor, Advanced Cancer","enrollment":174},{"nctId":"NCT02205047","phase":"PHASE2","title":"Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2015-07-15","conditions":"Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach, Epidermal Growth Factor Receptor (EGFR) Protein Overexpression","enrollment":172},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT02358031","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-03-19","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":882},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT03519295","phase":"PHASE2","title":"A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2018-07-03","conditions":"Anal Cancer","enrollment":97},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT04420884","phase":"PHASE1, PHASE2","title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2020-07-22","conditions":"Solid Neoplasms","enrollment":248},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT06943820","phase":"PHASE1, PHASE2","title":"AK129 Combination Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-21","conditions":"Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma","enrollment":230},{"nctId":"NCT03914443","phase":"PHASE1","title":"A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Center, Japan","startDate":"2019-05-07","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT00324415","phase":"PHASE2","title":"Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2006-09","conditions":"Anal Cancer","enrollment":45},{"nctId":"NCT04328948","phase":"PHASE3","title":"A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC","status":"RECRUITING","sponsor":"National Cancer Center, Japan","startDate":"2020-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":280},{"nctId":"NCT04478292","phase":"PHASE3","title":"A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2021-03-01","conditions":"Hepatoblastoma","enrollment":330},{"nctId":"NCT04456322","phase":"PHASE3","title":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-08-17","conditions":"Nasopharyngeal Carcinoma","enrollment":381},{"nctId":"NCT03944915","phase":"PHASE2","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2019-08-26","conditions":"Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":207,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CDDP, 5 Fu","genericName":"CDDP, 5 Fu","companyName":"Gustave Roussy, Cancer Campus, Grand Paris","companyId":"gustave-roussy-cancer-campus-grand-paris","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}